MicroPort Scientific : ® Lifesciences Attends CDS2017

Chongqing, China - From November 23 to November 25, Shanghai MicroPort Lifesciences Co., Ltd. ('MicroPort Lifesciences') attended the 21th Scientific Meeting of the Chinese Diabetes Society ('CDS2017') and displayed its La Fenice Hypophyseal Hormone Infusion Pump and La Fenice Insulin Pump in its booth. The CDS2017 was hosted by Chinese Medical Association and Chinese Diabetes Society and organized by Chongqing Medical Association.

Themed on 'Collaborative Innovation and Integrated Development' and combined with the essences of ADA and EASD meeting in this year, the CDS2017 displayed the latest academic advancement and clinical application of the diabetes treatment industry. It also enlarged the extension of the diabetes and strengthened interdisciplinary cooperation. Experts of diabetes care and endocrinal management were invited to exchange ideas on clinical practice.

During the conference, many experts, including President of Chinese Endocrinologist Association Guang Ning of Shanghai Ruijin Hospital, visited MicroPort Lifesciences booth to get a better understanding in its products. Academician Ning said, La Fenice Hypophyseal Hormone Infusion Pump not only has good effect on the treatment of Idiopathic hypogonadotropic hypogonadism ('IHH') but also could help diagnose and treat idiopathic central secondary amenorrhea, and regulate menstrual cycles and boost the chance of pregnancy for patients with non-obesity polycystic ovarian syndrome ('PCOS').

Equipped with pulsatile infusion via micro pump technology, La Fenice Hypophyseal Hormone Infusion Pump works as an artificial hypothalamus - it stimulates hypophysis to excrete follicle-stimulating hormone ('FSH') or luteinizing hormone ('LH') by simulating pulsatile excretion of GnRH in order to make patients recover from abnormally physiological adjustment function. It is the first domestically developed GnRH pulsatile pump. Since its market launch, a total of 134 babies were born with the help of La Fenice Hypophyseal Hormone Infusion Pump.

Professor Jie Wen of Huashan Hospital of Fudan University offered previous suggestion on MicorPort Lifesciences' new generation 1.8T Insulin Pump. La Fenice Insulin Pump works as an artificial pancreas. It can maintain stable blood glucose for the patient effectively and safely for throughout the day and night with its unique parameter index. La Fenice Insulin Pump is specially designed for Chinese patients based on their eating habits and lifestyle. It is easy to operate and has precise dose. The device offers intensive treatment for diabetics in perioperative period to help them achieve faster postoperative recovery. La Fenice Insulin Pump has been widely used in clinic and won recognition from industry experts since its market launch.

Since establishment, MicroPort Lifesciences primarily focuses on the development and manufacturing of hypophyseal hormone infusion pump, insulin pump, and relevant disposables, to offer affordable and effective solution and service to patients suffering from diabetes and endocrinal diseases. In the future, MicroPort Lifesciences will continue to devote itself to researching and developing more precise, more minimally invasive and smarter medical devices of diabetes and endocrine system, to benefit more patients and contribute to the healthcare industry.

About MicroPort

MicroPort Scientific Corporation (the 'Group') is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words 'believe', 'intend', 'expect', anticipate', 'project', 'estimate', 'predict', 'is confident', 'has confidence' and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort's management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2018 MicroPort Scientific Corporation

CONTACT:

Amanda Zhang Corporate Culture & Public Relations Director Shanghai MicroPort Medical (Group) Co., Ltd. (HQ) Tel: [phone]-6989 Email: [e-mail]